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We present, here, a detailed and curated map of molecular
interactions taking place in the regulation of the cell cycle by
the retinoblastoma protein (RB/RB1). Deregulations and/or
mutations in this pathway are observed in most human
cancers. The map was created using Systems Biology
Graphical Notation language with the help of CellDesigner
3.5 software and converted into BioPAX 2.0 pathway
description format. In the current state the map contains 78
proteins, 176 genes, 99 protein complexes, 208 distinct
chemical species and 165 chemical reactions. Overall, the
map recapitulates biological facts from approximately 350
publicationsannotatedinthediagram.Thenetworkcontains
more details about RB/E2F interaction network than existing
large-scale pathway databases. Structural analysis of the
interaction network revealed a modular organization of the
network, which was used to elaborate a more summarized,
higher-level representation of RB/E2F network. The simpli-
ﬁcation of complex networks opens the road for creating
realistic computational models of this regulatory pathway.
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Introduction
The cell cycle is the succession of four phases called G1, S, G2
andM.Individingcells,DNAreplication(Sphase)andmitosis
(M phase) alternate (Alberts et al, 1994), and are separated by
two gap phases, G1 and G2 phases. In quiescent cells, the cells
are considered to be in G0 phase. When they receive external
signals, such as growth factors, a series of activations push the
cell from a G0 to a G1 state and entersthe cell cycle. The whole
process of cell division is mainly orchestrated by complexes
composedoftwosubunits,akinaseandacyclinpartner.These
complexes phosphorylate a certain number of proteins, either
activating or inhibiting them. Among them, the retinoblasto-
ma tumour suppressor protein RB (RB1) is a key regulator in
cell-cycle entry (transition G1/S). It sequesters a family of
transcription factors, the E2Fs, responsible for the transcrip-
tion of many genes involved in cell-cycle regulation, DNA
replication and other functions like the activation of the
apoptotic pathway (Mulleretal,2001).RBfunctions asabrake
inthecellcycle,whichisreleasedwhenexternalsignalstrigger
S-phase entry. The main targets of the external signals are the
G1 cyclin/CDK complexes.Once active, the complexes, among
them CycD1/CDK4,6, act as starters of the cell cycle (Novak
et al, 2007) and phosphorylate RB, which then releases E2F
(DeGregori, 2004).
RB is a member of a family of proteins called the pocket
proteins (Knudsen and Wang, 1997). These proteins RB, p107
andp130,sharesequencesimilarities,especiallyinthe‘pocket
domain’ (Stevaux and Dyson, 2002), which is responsible for
their repressor function. RB protein contains domains where
the binding sites for co-repressors (E2F proteins and viral
oncoproteins) are situated. These sites are subjected to most
mutations.
RBisatumoursuppressorgene.Becauseofitsimplicationin
so many, if not all, cancers (Sherr and McCormick, 2002), the
study of RB regulation requires a special attention.
More speciﬁcally, the RB/E2F pathway is commonly
deregulated in cancer through genetic or epigenetic mechan-
isms, resulting in E2F activation. Several common oncogenes
(involved in many cancer types) are the activators of the
pathway, whereas several common tumour suppressor genes
areinhibitorsofthepathway.Forexample,cyclinD1(CCND1),
E2F3 and the two cyclin-dependent kinases CDK4 and CDK6
can be activated by translocation, ampliﬁcation or mutation,
whereas RB (RB1) and the cyclin-dependent kinase inhibitors
p16INK4a (CNKN2A) and p15INK4b (CDKN2B) can be
inactivated by point mutation, homozygous deletion or DNA
methylation. In addition, RB can be inactivated by several
oncogenic viral proteins including E7 from human papilloma-
virus, which is responsible for more than 90% of cervical
carcinomas (Munger et al, 2001). Tumour suppressor gene
inactivation is found not only in sporadic tumours but also in
tumour-prone families. Germline mutations of RB1 results in
retinoblastoma with a high penetrance early in young
individuals and late in life in sarcomas and lung and bladder
carcinomas (Knudson, 1971; Nevins, 2001; Giacinti and
Giordano, 2006). Germinal mutations of p16INK4a results in
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www.molecularsystemsbiology.commelanomas (Hussussian et al, 1994). Finally, the importance
of the RB/E2F pathway in tumour formation based on genetic
or epigenetic arguments, has been conﬁrmed by in vivo
experiments using transgenic mice (Classon and Harlow,
2002).
Often, textbooks present a simpliﬁed picture of RB regula-
tion (Figure 1): mitogens activate CycD1/CDK complexes,
which phosphorylate RB, and which, in turn, releases the hold
on E2F transcription factors. E2F activity controls cell-cycle
progression.
However, the real picture of interactions around RB is much
more complex due to combinatorial complexity and the
number of important regulators, which are not taken into
accountinthesimplepathwayview.Therearenotonlyseveral
E2F transcription factors but also several proteins besides RB
with which the E2F proteins bind to be inactivated. Moreover,
the RB-related proteins not only can sequester the E2Fs but
also can actively repress transcription. There are 10 known
E2F proteins—7 of which bind to dimerization partners (DP1
and DP2) to become active—that can associate with the three
pocket proteins RB, p107 and p130, and proteins from the
polycomb group. These E2F proteins can be (1) activators of
transcription (E2F1, E2F2 and E2F3a) or (2) repressors of
transcription (E2F3b, E2F4, E2F5 and E2F6). The last E2F
familyproteins,E2F7a,E2F7bandE2F8,formhomodimers,do
not bind to pocket proteins and seem to repress transcription.
We believe that this complexity has to be taken into account
in any realistic consideration of the RB network (such as the
creation of a computational model). Thus, we stated our
problem as a very careful and focused consideration of the
whole corpus of available biological facts published in high-
level biological literature to reconstruct a detailed network of
interactions around RB protein.
We started from the simpliﬁed picture (Figure 1) and added
several tens of proteins involved in cell-cycle regulation,
carefully connecting them to the rest of the network by means
of known biochemical transformations. There were several
questions that had to be answered during this reconstruction:
(1) What should the language be for such a detailed descrip-
tion? It should be standard and expressive enough to
readilyincorporateavailablebiological facts.Achoicewas
made to use Systems Biology Graphical Notation (SBGN)
standard partially implemented in CellDesigner software
(Kitano et al, 2005). This choice also deﬁned for us the
level of details that we should keep in the description.
(2) How to deliver the collected information to the public?
Together with CellDesigner diagram, we chose to use the
BioPAX format for storing pathway information. An
automatic conversion tool from CellDesigner (Funahashi
et al, 2003) to BioPAX was developed (Zinovyev et al,
2007).
(3) How to deﬁne the ‘borders’ of RB pathway? RB interacts
withmorethan100proteins(MorrisandDyson,2001).We
chose to concentrate mainly on genes involved in cell-
cycle regulation and in apoptosis entry.
(4) How to make the resulting detailed network usable and
understandable? We performed a structural analysis of the
resulting network, and it was found that the network has a
modular structure. A module was deﬁned as a cluster of
relevant cycles in the reaction graph. A special software,
BiNoM, plugin of Cytoscape (Zinovyev et al, 2007), was
developed to perform such analysis (see Materials and
methods).
(5) How to maintain and expand the pathway? Aweb-page is
associated with the pathway (http://bioinfo-out.curie.fr/
projects/rbpathway/) and will be regularly updated as
some new papers appear and with the input we expect
from the RB experts worldwide (listed in ‘Contributors’
section on our web-page).
One purpose behind the construction of this diagram, once
validated, is to provide a map of RB/E2F pathway that can
become not only a reference while studying different cancers
and mutations but also a tool to analyse formally the pathway
and predict its behaviour in response to different types of
deregulations (Nevins, 2001).
Table I recapitulates all current names for genes used in this
article and their corresponding HUGO names. RB, p107 and
p130 are the common names for the proteins referenced as
RB1, RBL1 and RBL2 (HUGO names), respectively.
A comprehensive map of RB/E2F pathway
Map of the pathway in CellDesigner and BioPAX
representations
Figure 2 shows the resulting comprehensive map of RB
pathway. The diagram utilizes SBGN system (http://
www.sbgn.org) to represent proteins and their speciﬁc
modiﬁcations,proteincomplexesandgenes,aswellasvarious
protein transformations (binding, unbinding, phosphory-
lation, acetylation, transport and so on) and their effects of
Mitogens
CDK4,6
Cyclin D1
CKI
RB RB-P
E2F
Cell cycle 
progression
Figure 1 Textbook view of the RB/E2F pathway. When CycD1/CDK4,6 is
activated, it phosphorylates RB, which in turn is inactivated and releases E2F
transcription factors leading to cell proliferation.
A comprehensive map of RB/E2F pathway
L Calzone et al
2 Molecular Systems Biology 2008 & 2008 EMBO and Nature Publishing Groupactivation or inhibition of chemical reactions, including
transcriptional activation or inhibition.
In the general organization of the diagram, there is a part
representing the set of genes regulated by the E2F family of
transcription factors (2A) and another one representing the
location of the different proteins in the three different cellular
compartments (the nucleus, nucleolus and cytoplasm) (2B).
The resulting map has a total of 78 proteins, which are
represented in 208 distinct chemical species (158 of them
are located in the nucleus, 47 in the cytoplasm and 3 in the
nucleolus), 526 reactions and regulations (among them,
57 protein associations, 13 protein dissociations, 68 post-
translational modiﬁcations, 361 transcriptional regulations
and 27 transport pseudo-reactions), 176 genes, and compiles
experimental results from more than 350 publications (301
research papers and 56 reviews).
Once compiled in CellDesigner software, the pathway
information was translated into BioPAX format using BiNoM
Cytoscape plugin (see Materials and methods). All the ﬁles in
SBML and BioPAX formats are available in the Supplementary
information. An interactive version of the map can also be
found on the web site.
We compared our RB/E2F map to existing pathway
databases such as Reactome (Joshi-Tope et al, 2005) or
Transpath (Krull et al, 2003) and concluded that we provide
a more systematic description of RB/E2F network than
that contained in the general purpose pathway databases
(details at http://bioinfo-out.curie.fr/projects/rbpathway/
Comparison.html).
Modular decomposition of the pathway
Using clustering of relevant cycles in the reaction graph (see
Materials and methods for details) and consequent manual
curation, the detailed RB pathway was decomposed into 16
network modules. As a result, almost every module can be
thought as a detailed sequence of events that occur with a
particular protein or protein complex whose name designates
the whole module. Thus, we identiﬁed RB, E2F1-3, E2F4-5,
E2F6-8,CycC/CDK3,CycH/CDK7,CycD1/CDK4,6,CycE1/CDK2,
CycA2/CDK2, CycB1/CDC2, p16INK4a/p15INK4b, p27KIP1/
p21CIP1, CDC25C and Wee1, APC and Apoptosis entry
modules. Eight additional modules were considered represen-
ting the transcriptional targets of each of the E2Fs described in
the RB/E2F map.
Identiﬁcation of these modules allowed us to compile a
modular RB pathway view (Figure 3), where network modules
Table I List of protein names used in the diagram and the corresponding HUGO
names
Cell designer name Used name HUGO name
AKT1 AKT1 AKT1
APC Anaphase-promoting complex
ATM ATM ATM
ATR ATR ATR
BAT8 G9a BAT8
BMI1* BMI1 PCGF4
CDC14A CDC14A CDC14A
CDC2 CDK1 CDC2
CDC20 CDC20 CDC20
CDC25C CDC25C CDC25C
CDC37 CDC37 CDC37
CDH1* CDH1 FZR1
CDK2 CDK2 CDK2
CDK3 CDK3 CDK3
CDK4 CDK4 CDK4
CDK6 CDK6 CDK6
CDK7 CDK7 CDK7
CDKN3 KAP1 CDKN3
CHEK1 Chk1 CHEK1
CHEK2 Chk2 CHEK2
CREBBP CBP CREBBP
cyclin A2* cyclin A2, CycA2 CCNA2
cyclin B1* cyclin B1, CycB1 CCNB1
cyclin C* cyclin C, CycC CCNC
cyclin D1* cyclin D1, CycD1 CCND1
cyclin E1* cyclin E1, CycE1 CCNE1
cyclin H* cyclin H, CycH CCNH
DP1* DP1 TFDP1
DP2* DP2 TFDP2
E2F1 E2F1 E2F1
E2F2 E2F2 E2F2
E2F3 E2F3 E2F3
E2F4 E2F4 E2F4
E2F5 E2F5 E2F5
E2F6 E2F6 E2F6
E2F7 E2F7 E2F7
E2F8 E2F8 E2F8
EED EED EED
EHMT1 Eu-HMT1 EHMT1
EP300 p300 EP300
EPC1 EPC1 EPC1
EZH2 EZH2 EZH2
GSK3B GSK3B GSK3B
HDAC1 HDAC1 HDAC1
HP1gamma* HP1gamma CBX3
HSP90 HSP90 family
MAX MAX MAX
MDM2 MDM2 MDM2
MEL-18* MEL-18 PCGF2
MGA MGA MGA
MNAT1 MAT1 MNAT1
NBS1 NBS1 NBS1
p107* p107 RBL1
p130* p130 RBL2
p14ARF* p14ARF CDKN2A
p15INK4b* p15INK4b CDKN2B
p16INK4a* p16INK4a CDKN2A
p18INK4c* p18INK4c CDKN2C
p19INK4d* p19INK4d CDKN2D
p21Cip1* p21Cip1 CDKN1A
p27Kip1* p27Kip1 CDKN1B
p53* p53 TP53
p57Kip2* p57Kip2 CDKN1C
PCAF P/CAF PCAF
PCNA PCNA PCNA
PHC1 Mph1 PHC1
PKMYT1 Myt1 PKMYT1
PP1 PP1 PP1
pRB* RB, pRB RB1
RING1 RING1 RING1
RYBP RYBP RYBP
SERTAD1 SERTAD1 SERTAD1
Table I Continued
Cell designer name Used name HUGO name
SIN3B SIN3B SIN3B
SUV39H1 SUV39H1 SUV39H1
SWI/SNF SWI/SNF SWI/SNF
TFIIH* TFIIH
TOPBP1 TOPBP1 TOPBP1
WEE1 WEE1 WEE1
Asterisks areadded to the CellDesignernameseach time the name used does not
correspond to the HUGO name.
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information about these relations is derived from the detailed
diagram. For example, in the detailed map, E2F1 is phos-
phorylated by CycA2/CDK2 and is subsequently recognized
for degradation, which is translated in the modular map by
CycA2/CDK2 module inhibiting E2F1-3 module.
Figure 2 The textbook pathway of RB has been expanded by integrating data from the literature. The E2F transcription factors (represented here by single proteins in
the nuclear compartment) are connected by activation and inhibition arrows to their gene targets. (A) Map of target genes of E2F transcription factors. Each E2F
associates with different cofactors to activate or inhibit the transcription of many genes; pointed arrows mean activation and ﬂat arrows mean inhibitions (B) Map of
protein–protein interaction network. Each icon on the diagram represents distinct chemical species. See Kitano and co-workers’ description of CellDesigner’s standard
notation (Kitano et al, 2005) for a detailed meaning of shapes. When the information is available (from Atlas Oncology web-page: www.atlasgeneticsoncology.org/),
tumour suppressor genes and the corresponding proteins are coloured in blue and oncogenes in red, the other proteins are in green. To read and navigate through the
map, visit our webpage: http://bioinfo-out.curie.fr/projects/rbpathway/. The map is clickable and allows easy access to all included information (such as literature
references or standard protein ids) and hyperlinked to other databases.
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ﬁgures are provided below only for E2Fs and RB modules
(Figure 4). However, the ‘clickable’ modular view leading
to a description and the corresponding ﬁgures of each
of the modules can be found in the Supplementary
information (http://bioinfo-out.curie.fr/projects/rbpathway/
Modules.html).
The RB module
Two cycles appearin this module revealing tworolesof RB. (1)
A transcriptional repressor: HDAC1 is a marker of transcrip-
tional repression and seems to require the chromatin
remodeler SWI-SNF to form a repressor complex with DP1/
E2F1/RB (Frolovand Dyson,2004). The complexrecruitsboth
HP1-g and SUV39H1 and continues to prevent transcription
(Nielsen et al, 2001). (2) A repressor of E2F1/DP1: RB binds to
E2F1/DP1 and blocks its transcriptional activity. The afﬁnity
between E2F1/DP1 and RB is decreased through sequential
phosphorylations by the Cyclin/CDK complexes. The ﬁrst
phosphorylations by CycC/CDK3 favours the passage from G0
to G1 phase, then CycD1/CDK4,6 modiﬁes its conformation
andreleasesHDAC1(Zhangetal,2000),revealinganewsiteof
phosphorylation targeted by CycE1/CDK2 (Vidal and Koff,
2000; Muchardt and Yaniv, 2001). The phosphorylation by
CycD1/CDK4,6 already allows some genes to be transcribed
(such as Cyclin E).
The complexes CycD1/CDK4 and CycD1/CDK6 act as
sensors of growth factors. When activated, they precipitate
the cells into S phase by further phosphorylating RB
(Weinberg, 1995; Planas-Silva and Weinberg, 1997).
When RB is hyperphosphorylated, the complex dissociates
and E2F1/DP1 is released from the inactivecomplex. Later, RB
is dephosphorylated by the phosphatase PP1 towards the end
of M phase and able to repress E2Fs again (Vidal and Koff,
2000).
The E2F transcription factors modules
The pocket proteins RB, p130 and p107 inhibit a family of
transcriptionfactors,theE2F,throughassociationandcanalso
act as active repressors by recruiting other partners.
We already mentioned three subgroups of E2F transcription
factors. The ﬁrst group contains activators of transcription:
E2F1, E2F2 and E2F3a, which bind to RB; the second one
regroups inhibitors of transcription: E2F3b, E2F4 and E2F5,
which bind to either p107 or p130 and to some extent RB; and
the third group includes E2F6, E2F7 and E2F8, which do not
need to bind to pocket proteins to become active repressors of
transcription. These three groups correspond to three different
modules that are described below.
Activator E2F1-3 module
The E2F1-3 module includes the E2F activator family of
transcription E2F1, E2F2 and E2F3a. Even though the proteins
slightly differ in their cell-cycle role, we chose to describe the
three E2F transcription factors as one, as they share a lot of
functionalsimilarities.Inafutureversionofthepathway,weplan
to differentiate the activity of the three transcription activators.
Experiments show that dimerization between E2F1 and its
partner DP1 is stable and that E2F1 stimulates nuclear
localization of DP1 (Magae et al, 1996). E2F1/DP1 is
E2F8_targets E2F6_targets
E2F7_targets
E2F4_targets
E2F5_targets
E2F2_targets
E2F3_targets E2F1_targets
E2F6-8 E2F4-5 E2F1-3
RB p16/p15
CycC:CDK3
CycD1:CDK4,6 CycE1:CDK2
CycA2:CDK2
CycB1:CDC2
CycH:CDK7
p27/p21
CDC25C
WEE1
APC
Apoptosis
entry
Figure 3 Modular view of the comprehensive map presented in Figure 2. The comprehensive map has been simpliﬁed using curated structural analysis techniques to
divide the graph in modules. The links between the nodes represent the inﬂuence that a module has on the others. There are 16 protein modules (green rounded
rectangles) and 8 E2F target gene modules (yellow rectangles).
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protein and p300—to stabilize the E2F1 protein (Frolov and
Dyson, 2004). The acetylated complex is capable of binding to
PCAF to form an active dimer. The complex ability of binding
to DNA on the promoter sites of its target genes along with its
transcriptional activity isincreased duringtheG1–S transition.
At G2, the complex is phosphorylated by CycA2/CDK2
(He and Cress, 2002). The afﬁnity between E2F1 and DP1 is
Figure 4 Cytoscape view of (A) E2F1-3 module and (B) RB module.
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(Tsantoulis and Gorgoulis, 2005) and the release of PCAF. The
proteins undergo further modiﬁcations before degradation:
E2F1 is deacetylated by HDAC1 (Martinez-Balbas et al, 2000),
dephosphorylated and phosphorylated de novo during S phase
by TFIIH kinase for rapid degradation (Ianari et al, 2004).
On DNA damage, the complex PCAF/E2F1/DP1 can be
phosphorylated and stabilized either by CHEK1 and CHEK2
through phosphorylation at Ser-364 or by ATM and ATR
(Dimova and Dyson, 2005; Powers et al, 2004), preventing
E2F1 ubiquitination (Wang et al, 2004). E2F1 mediates the
transcription of many genes involved in apoptosis. However,
E2F1transcriptional activitycan alsobe inhibitedwhen bound
to the topoisomerase TopBP1 to give time to the cell to repair
the damage (Liu et al, 2003).
Repressor E2F4–5 module
E2F4 associates successively with two different pocket
proteins: p130 in quiescent cells and p107 in proliferating
cells. E2F4 is initially found in the cytoplasm. When in
complex, E2F4 is translocated in the nucleus, whereit acts as a
repressor of transcription during G0 and G1 phases (Verona
et al, 1997). Once in the nucleus, the complex binds to DNA
and recruits some co-repressors of transcription: the chro-
matin remodeler Sin3B, the deacetylase histone HDAC1 and
the methyltransferase histones SUV39H1 (Rayman et al, 2002;
Liu et al, 2005).
At the G0–G1 transition, when the quiescent cells receive
signals from growth factors, p130 starts to be phosphorylated
and gets dissociated from the complex it was forming with
E2F4/DP2. Later, p130 can also be phosphorylated by CycD1/
CDK4,6 and CycE1/CDK2 when present and degraded in late
G1. It is then replaced by p107 (Farkas et al, 2002). When
E2F4/DP2 is in complex with p107, it continues to repress
transcription of target genes until it is phosphorylated by
CycD1/CDK4,6. E2F4 is then translocated to the cytoplasm,
where it can no longer repress transcription, whereas both
p130 and p107 are able to inhibit CycE1/CDK2 and CycA2/
CDK2 activities (Litovchick et al, 2004).
In this module, E2F3b and E2F5 should also be considered.
Their repressive role in the pathway is not described yet but
will be detailed in future versions of the pathway.
Repressor E2F6–8 module
E2F6 seems to play a role in S-phase entry. It binds to both DP
partners, DP1 and DP2, in the cytoplasm, and the complexes
are then translocated in the nucleus. As opposed to other E2F
family members, E2F6 does not associate with pocket proteins
but rather recruits some proteins from the polycomb group
(PcG) to repress transcription.
The ﬁrst polycomb group with which E2F6 is involved
includes BMI1, Mel-18, PHC1, RING1 and RYBP and acts
as a repressor of transcription (Trimarchi et al, 2001;
Sa ´nchez-Beato et al, 2004). Similarly, E2F6, Max and HP1-g
bind to form a complex that has also revealed a repressive
transcription role in quiescent cells (Ogawa et al, 2002).
However, E2F6 seems to intervene in other transitions of the
cell cycle than only that of G0–G1. Another complex involving
EPC1 and EZH2 has been found in proliferating cells: E2F6/
DP1 is repressing transcription when in complex with EPC1
alone or with both EPC1 and EZH2 (Attwooll et al, 2005).
E2F6/DP1 binds consecutively to EPC1 and then to both EZH2
and EED. The roles of the different complexes are not clearly
established yet and more experiments will be needed to
conﬁdently describe their speciﬁc actions in proliferating and
quiescent cells.
E2F7 and E2F8 regulations have not been carefully deﬁned
in our pathway yet. Both are known to inhibit transcription
although (de Bruin et al, 2003; Logan et al, 2005). The details
will be added asmorepublications on their role in RB pathway
appear.
RB pathway transcriptional activity modules
The eight ‘E2F*_targets’ modules correspond to the gene
targets of the eight E2F transcription factors. The three
transcription factors E2F1, E2F2 and E2F3, although not
having well-documented differences at the level of protein–
protein interactions and represented by a generic entity in
our diagram (Figure 2B), show their speciﬁcities at the
transcription level. For this reason, the generic entity is
decomposed into the three individual components in the
upper part of the diagram (Figure 2A).
According to our diagram, RB/E2F pathway is a self-
regulating molecular mechanism, as there exist multiple
positive and negative feedbacks through transcription: among
the 78 proteins described in the diagram, 23 are targets of the
E2Fs transcription factors, both activators and inhibitors. The
structure of these feedbacks is detailed in Supplementary
Figure S1 and Supplementary Table S1. E2F1 is a target gene
for all E2Fs with the exception of E2F5. In turn, E2F1 regulates
expressionofE2F1,E2F2,E2F6,E2F7andE2F8genesresulting
in several negative and positive feedback control circuits.
To analyse the differences between the E2Fs and their roles
in other contexts, we calculated the signiﬁcance of the
overlaps of all E2F1-8 transcriptional targets with other
known pathways such as MSigDB database (BROAD, MIT)
(Subramanian et al, 2005). The results are provided in
Supplementary Table S2. As expected, these lists have highly
signiﬁcant overlaps with cell-cycle-, G1–S transition-, Rb/
E2F- or p21-related pathways. Some other overlaps highlight
the involvement of RB/E2F in some differentiation-related
pathways and reciprocally. However, only E2F1 target list is
linked to various apoptosis-related pathways (APOPTOSIS_
GENMAP, APOPTOSIS_KEGG, DEATH_PATHWAYand others).
In particular, E2F1, but not the other E2Fs, targets p53 tumour
suppressor gene in RB/E2F pathway. This conﬁrms the recent
ﬁndings that E2F1 is the only speciﬁc inducer of apoptosis
among the E2F transcription factors, even though its level can
beregulatedbyotherE2Fs(LazzeriniDenchiandHelin,2005).
Case study of bladder tumour data
As an example of the potentialities of the map we have
assembled, we performed a study on 55 bladder tumours
(Stransky et al, 2006). This study exempliﬁed how the map
and its modular decomposition can be used to explain the
A comprehensive map of RB/E2F pathway
L Calzone et al
& 2008 EMBO and Nature Publishing Group Molecular Systems Biology 2008 7differences between two different tumour progression
pathways and/or different stages of cancer progression.
More speciﬁcally, we analysed transcriptome and compara-
tive genomics hybridization data collected for 55 patients with
bladder cancers. We veriﬁed which groups of genes (modules)
are up- or downregulated in invasive cancers and identiﬁed
two different paths that both lead to invasive aggressive
cancers. This study conﬁrmed known facts about bladder
cancer, for example overexpression of CCND1 in low-grade
tumours, and led to new observations, for example down-
regulation of E2F4-5, E2F6-8, Wee1, APC modules in invasive
cancers.
The approach and our map can similarly be used for
comparing other biological contexts. Indeed, further analyses
will be developed to obtain more insights into molecular
mechanisms of cancer progression. The details and results of
this preliminary study can be found on our webpage: http://
bioinfo-out.curie.fr/projects/rbpathway/case_study.html.
Discussion
In this paper, we present a comprehensive representation of
the molecular interactions regulating RB activity in cell-cycle-
related events. We were able to integrate an important amount
of information and represent it in a hierarchical manner, with
both a detailed and a summarized and readable representa-
tion. This map reﬂects our understanding of the numerous
publications we used to build the pathway. Our study opens
perspectives for understanding functioning of RB/E2F path-
way and for integrating this information into realistic
computational models of mammalian cell cycle.
Pathwaydatabaseshaverapidlygrownduringthelastyears.
There exists a number of publicly available or commercial
databases:Reactome(Joshi-Topeetal,2005),KEGG(Kanehisa
and Goto, 2000), Transpath (Krull et al, 2006), Ingenuity
(www.ingenuity.com), BioCyc (Krummenacker et al, 2005),
and so on. They implement different data models, represent
molecular interactions at different level of biological details
and specialize in different aspects of cellular interactome
description. These databases provide an important source of
information; however, due to large-scale effort undertaken for
their creation, it is difﬁcult to guarantee that the interaction
information collected for some speciﬁc part of the cellular
network is exhaustive. Moreover, biological publications often
contain ambiguous statements or even contradictions to other
publications, such that for some speciﬁc biological pathway,
normal level of expertise of a pathway database curator may
notbesufﬁcienttoresolvetheseissuesinasystematicandself-
consistent way.
When a structural model of a speciﬁc complex molecular
process is created, the pathway databases can be used to build
a model draft that needs to be carefully curated by experts
specialized in this particular ﬁeld. The resulting diagram
presents a consensus point of view of the experts in which
ambiguities and contradictions are resolved according to their
opinion. As examples of such focused studies,we can mention
reconstruction of human cell-cycle events by Kohn (Kohn,
1999), comprehensive maps of EGFR pathway (Oda et al,
2005)orToll-likereceptorsignallingpathway(OdaandKitano,
2006) and so on.
Our RB pathway reconstruction enlarges this collection.
Detailed knowledge of this pathway is necessary for under-
standing deregulation of mammalian cell cycle in human
cancers where the RB network is very frequently affected by
genetic and epigenetic alterations. Using automated querying
of Reactome database, we conﬁrmed that the reconstruction of
RB pathway we present in this paper is more systematic and
comprehensive.
Standardization of pathway knowledge representation is of
outmost importance in the process of pathway curation
(Hucka et al, 2003). In recent years, knowledge representation
standards have emerged in Systems Biology and gained
momentum in the community (Klipp et al, 2007; Le Novere
et al, 2005). SBGN standard partially implemented in
CellDesigner software showed good performance in large-
scale efforts such as PANTHER database (Mi et al, 2007) and
was adopted in this study. It was conﬁrmed that this tool
presents a practical compromise between readability of the
resulting diagram and the exhaustiveness of the interaction
representation. Biologists who are familiar with it can use
CellDesigner as an ‘input’ device for entering experimental
facts in a well-deﬁned framework.
To facilitate the manipulation and analysis of the big
pathway diagram, we developed BiNoM software (Zinovyev
et al, 2007) which, among many other features, imports
information from CellDesigner to Cytoscape (Shannon et al,
2003). More speciﬁcally, methods of pathway structure
analysis that we implemented in BiNoM allowed to deﬁne a
modular structure of RB pathway and create its higher-level
modular view (see Materials and methods for details).
Importantly, this higher-level pathway representation is fully
based on the underlying detailed map and helps navigate
through it. If necessary, it is always possible to referto detailed
mechanisms of the individual module’s functioning. Similar
approach to modular pathway modelling is implemented in
ProMoTsystem (Saez-Rodriguez et al, 2006).
The most up-to-date and comprehensive description of the
pathway, CellDesigner and BioPAX ﬁles are available on the
web-page with Supplementary information. The interactive
online version of the pathway diagram is accessible
at: http://bioinfo-out.curie.fr/projects/rbpathway/complete_
network.htm. Such functionalities aszooming orcentering the
screen on a molecule, complex or reaction, isolating parts of
the diagram (modules) in both Cytoscape and CellDesigner
views facilitate the navigation through the network and
the extraction of speciﬁc information. The CellDesigner
map ﬁle was used to automatically generate a navigable web
site, allowing to access the pathway information details,
including literature references and connection to some other
databases, in few clicks. Using BiNoM software, such
interactive online representations of the pathway diagrams
can be automatically created for other large CellDesigner
diagrams.
Further directions we preview for this study include (1)
creating a computational qualitative model of the regulationof
mammalian cell cycle by RB; (2) superimposing this model
with available data on genetic/epigenetic alteration status of
key proteins in tumour samples of certain cancers (such as
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update of the information collected in the pathway.
Materials and methods
ThepathwayisavailableinSBMLformatfromtheBioModelsdatabase
(http://www.ebi.ac.uk/biomodels) with the accession number MOD-
EL4132046015.
BiNoM
CellDesigner 3.5 version (Funahashi et al, 2003) was used to enter
biological facts from a carefully studied selection of papers (see the
whole bibliography on the web site with Supplementary information).
Whenever the details of a biological fact could not be naturally
expressed with CellDesignerstandard notations,it wasﬁxed and some
solution was proposed. For example, we added a notation (co-factor)
todescribeallthecomponentsinterveninginthetranscriptionofgenes
mediated by the E2F family proteins. To perform reaction network
structural analysis, we also developed BiNoM Cytoscape plugin
(Zinovyev et al, 2007) available at http://bioinfo-out.curie.fr/pro-
jects/binom/.
When importing CellDesigner information into Cytoscape, the
graphical notation used to describe composition of complexes or
modiﬁcation status in CellDesigner was substituted by textual
description, such that the label of a chemical species would be
sufﬁcient to identify the species in a unique way. The general template
of the species label was the following:
Entity1 namejModification1jModification2j   
: Entity2 namejModifications   ½activej hmN @compartment
Here,‘:’ delimitates components of a complex if the species has several
components. Optional sufﬁxes ‘active’ or ‘hm’ describe active state of
the chemical species or N-homodimer state. Several examples of such
conversion are presented in Figure 5.
The reaction graph of CellDesigner is represented as a bipartite
reaction graph in Cytoscape. Two types of vertices are used in this
graph: reaction vertices and species vertices. An example of a little
network is provided in Figure 6.
Methods for extracting modules in BiNoM
A step-by-step method for creating the modular view of the RB/E2F
pathway is provided on the webpage. The directed bipartite graph,
representingthe RBreaction network inCytoscapewasanalysed using
the following steps:
(1) All strongly connected components were extracted using
the standard Tarjan’s algorithm, implemented in BiNoM,
and used in further analysis. A strongly connected
component is a subgraph, in which there exists a directed
path from any graph vertex to any vertex.
(2) Every strongly connected component was decomposed
into relevant cycles, using modiﬁcation of Vismara’s
algorithm (Vismara, 1997), implemented in BiNoM. A
relevant cycle is a cycle that can not be further decom-
posed into smaller cycles (Gleiss et al, 2001). A set of
relevant cycles is by deﬁnition the union of all minimum
cyclic bases. Therefore, it is a minimum unique cyclic
graph decomposition (Vismara, 1997). A minimal cycle
basis of a graph is a set of all independent cycles with
minimum summary length. In general, this set is not
unique.
(3) For the collection of cycles obtained at the previous step, a
simple agglomerative clustering algorithm with asym-
metric similarity (proportion of common nodes) was
applied: if a subgraph is included in another subgraph in
P450% of its vertices, it will be merged with that
subgraph. If a subgraph could be merged with several
other subgraphs, it would be merged with the one with
which it had the biggest intersection. If the intersection is
Figure 5 Examples of textual representation of species structure. In CellDesigner, information about sites of phosphorylation or acetylation, and so on can be showed
on the protein itself. A complex is represented as a black box surrounding the proteins composing the complex.
Figure 6 Example of a simple network converted from CellDesigner to Cytoscape. In Cytoscape, single proteins are represented by white squares and complexes by
grey squares.
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subgraph. This process was repeated until there was no
possibility to merge subgraphs.
(4) For every cycle union, the ‘majority rule’ (Ma et al, 2004)
was applied to classify all reactions from noncyclic part of
the network: all incoming and outgoing linear and
branching pathways were included in the cluster of cycles
to which most of them were initially attached. This gave
the initial deﬁnition of modules.
(5) Step 4 was repeated with some range of values of P (from
30 to 70%) to ensure that it gives a robust decomposition
of the network. The clustering in this range of the
parameter always gave the same number of modules.
(6) All resulting modules were carefully studied and named
according tothename oftheprotein(complex)with major
participation. In the process of manual curation, some
important reactions and regulations were re-assigned, and
some modules were split.
For extracting modules in RB reaction graph, we deﬁned a cycle in the
reactiongraphasanelementaryfunctionalunit.Tightlycoupledcycles
form the module core. There are two types of cycles in the RB/E2F
network: (1) cycles of mass ﬂow and (2) cycles of information
(perturbation)ﬂow.Intheﬁrstcase,acycleofreactionscorrespondsto
an elementary mode in Stoichiometric Network Analysis (Schilling
et al, 2000), but applied to the pseudo-monomolecular approximation
ofthereal reactionnetwork,whenthereactionAþB-Cisconsidered
as A-C and B-C with kinetic constants dependent on the other
reactionparticipantconcentrations.Thisapproximationisvalidwhen,
forexampleconcentrationofAismuchhigherthanthatoftheB.Then,
A in the reaction AþB-C is considered as a relatively slowly
changing environment.
As it is argued in Gorban and Radulescu (2007) (http://arxiv.org/
abs/physics/0703278v2), in a complex network dynamics, at a given
moment of time, it might be that only a small subset of reactions
functionsinatrulynonlinearmode(however,thissubsetchangeswith
time), and the others can be approximated as pseudo-monomolecular.
Thisway,thecombinatorialproblemofﬁndingtrueelementarymodes
is simpliﬁed. Similar decoupling is applied by Klamt et al (2006) for
studying both signal and mass ﬂows in the logical framework.
Numerous approaches for module extraction in reaction networks
have been developed during the past years (Ravaszet al, 2002; Stelling
et al, 2002). An approach based on T-invariants in Petri Nets (a notion
similar to elementary mode) was used by Sackmann et al (2006) to
deﬁnemodulesin metabolic networks. Agglomerative(Ma et al, 2004)
anddivisive (Holmeet al, 2003)hierarchicalclusteringsof reactions of
a metabolic network were also proposed based on the analysis of the
shortest paths. Our method is different, as it uses clustering subgraphs
(relevant cycles) rather than individual reactions.
Linking RB/E2F pathway to other signalling
pathways
To estimatethe signiﬁcanceof the overlap among E2F’starget lists and
MSigDB database, we applied the following classical hypergeometric
test to calculate the P-value:
p ¼
X minðK;nÞ
i¼k
K
i
  
N   K
n   i
  
N
n
  
where N is the total number of different genes in MSigDB signatures, K
is the number of genes in a pathway from MSigDB, n is the number of
genes inone of the lists of E2Fx transcriptional targets. Having in mind
multiple hypotheses testing, we considered only the overlaps with
Pp10
 6 as signiﬁcant.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
Acknowledgements
This project was partly funded by the EC contract ESBIC-D (LSHG-CT-
2005-518192), the PIC Re ´tinoblastome from Institut Curie, the PIC
Bioinformatique et Biostatistiques from Institut Curie and the Research
Networks Program in Bioinformatics from the High Council for
Scientiﬁc and Technological Cooperation between France and Israe ¨l
(Ministe `redes Affaires Etrange `res,Ministe `rede l’EducationNationale,
de l’Enseignement Supe ´rieur et de la Recherche). LC, AG, AZ and EB
are members of the team ‘‘Systems Biology of Cancer,’’ Equipe
labellise ´e par la Ligue Nationale Contre le Cancer. FR and AG are
membersoftheteam‘‘OncologieMole ´culaire,’’Equipelabellise ´eparla
Ligue Nationale Contre le Cancer. We thank Nicolas Stransky, Aure ´lie
He ´rault and Yves Allory for providing bladder tumour data and Simon
Saule for his valuable suggestions for the RB pathway map. We also
thank the anonymous reviewers for their useful and stimulating
comments.
References
Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J (eds). (1994)
Molecular Biology of the Cell. Garland Publishing, New York, USA
Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, Steensgaard P,
WagenerC,SardetC,MoroniMC,HelinK(2005)Anovelrepressive
E2F6 complex containing the polycomb group protein, EPC1, that
interacts with EZH2 in a proliferation-speciﬁc manner. J Biol Chem
280: 1199–1208
de Bruin A, Maiti B, Jakoi L, Timmers C, Buerki R, Leone G (2003)
identiﬁcation and characterization of E2F7, a novel mammalian
E2F family membercapableofblocking cellular proliferation. J Biol
Chem 278: 42041–42049
Classon M, Harlow E (2002) The retinoblastoma tumoursuppressor in
development and cancer. Nat Rev Cancer 2: 910–917
DeGregori J (2004) The Rb network. J Cell Sci 117: 3411–3413
Dimova DK, Dyson NJ (2005) The E2F transcriptional network: old
acquaintances with new faces. Oncogene 24: 2810–2826
Farkas T, Hansen K, Holm K, Lukas J, Bartek J (2002) Distinct
phosphorylation events regulate p130- and p107-mediated
repression of E2F-4. J Biol Chem 277: 26741–26752
Frolov MV, Dyson NJ (2004) Molecular mechanisms of E2F-dependent
activation and pRB-mediated repression. J Cell Sci 117: 2173–2181
Funahashi A, Tanimura N, Morohashi M, Kitano H (2003)
CellDesigner: a process diagram editor for gene-regulatory and
biochemical networks. BIOSILICO 1: 159–162
Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene
25: 5220–5227
Gleiss P, Stadler P, Wagner A, Fell DA (2001) Relevant cycles in
chemical reaction networks. Adv Complex Systems 4: 207–226
He Y, Cress WD (2002) E2F-3B is a physiological target of cyclin A.
J Biol Chem 277: 23493–23499
Holme P, Huss M, Jeong H (2003) Subnetwork hierarchies of
biochemical pathways. Bioinformatics 19: 532–538
Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H,
the rest of the SF, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden
A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II,
Hedley WJ, Hodgman TC, Hofmeyr JH, , et al , SBML Forum (2003)
The systems biology markup language (SBML): a medium for
representation and exchange of biochemical network models.
Bioinformatics 19: 524–531
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS,
Sheahan MD, Clark WH, Tucker MA, Dracopoli NC (1994)
Germline p16 mutations in familial melanoma. Nat Genet 8: 15–21
A comprehensive map of RB/E2F pathway
L Calzone et al
10 Molecular Systems Biology 2008 & 2008 EMBO and Nature Publishing GroupIanari A, Gallo R, Palma M, Alesse E, Gulino A (2004) Speciﬁc role for
p300/CREB-binding protein-associated factor activity in E2F1
stabilization in response to DNA damage. J Biol Chem 279:
30830–30835
Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E,
de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, Lewis S,
Birney E, Stein L (2005) Reactome: a knowledgebase of biological
pathways. Nucl Acids Res 33: D428–D432
Kanehisa M, Goto S (2000) KEGG: Kyoto encyclopedia of genes and
genomes. Nucl Acids Res 28: 27–30
Kitano H, Funahashi A, Matsuoka Y, Oda K (2005) Using process
diagrams for the graphical representation of biological networks.
Nat Biotech 23: 961–966
KlamtS,Saez-RodriguezJ,LindquistJA,SimeoniL,GillesED(2006)A
methodology for the structural and functional analysis of signaling
and regulatory networks. BMC Bioinformatics 7: 56
Klipp E, Liebermeister W, Helbig A, Kowald A, Schaber J (2007)
Systems biology standards—the community speaks. Nat Biotech
25: 390–391
Knudsen ES, Wang JY (1997) Dual mechanisms for the inhibition of
E2F binding to RB by cyclin-dependent kinase-mediated RB
phosphorylation. Mol Cell Biol 17: 5771–5783
Knudson AJ (1971) Mutation and cancer: statistical study of
retinoblastoma. PNAS 68: 820–823
Kohn KW (1999) Molecular interaction map of the mammalian
cell cycle control and DNA repair systems. Mol Biol Cell 10:
2703–2734
Krull M, Pistor S, Voss N, Kel A, Reuter I, Kronenberg D, Michael H,
Schwarzer K, Potapov A, Choi C, Kel-Margoulis O, Wingender E
(2006) TRANSPATH: an information resource for storing and
visualizing signaling pathways and their pathological aberrations.
Nucleic Acids Res 34: D546–D551
Krull M, Voss N, Choi C, Pistor S, Potapov A, Wingender E (2003)
TRANSPATH: an integrated database on signal transduction and a
tool for array analysis. Nucleic Acids Res 31: 97–100
Krummenacker M, Paley S, Mueller L, Yan T, Karp PD (2005)
Querying and computing with BioCyc databases. Bioinformatics
21: 3454–3455
Lazzerini Denchi E, Helin K (2005) E2F1 is crucial for E2F-dependent
apoptosis. EMBO Rep 6: 661–668
Le Novere N, Finney A, Hucka M, Bhalla US, Campagne F,
Collado-Vides J, Crampin EJ, Halstead M, Klipp E, Mendes P,
Nielsen P, Sauro H, Shapiro B, Snoep JL, Spence HD, Wanner BL
(2005) Minimum information requested in the annotation of
biochemical models (MIRIAM). Nat Biotech 23: 1509–1515
Litovchick L, Chestukhin A, DeCaprio JA (2004) Glycogen synthase
kinase 3 phosphorylates RBL2/p130 during quiescence. Mol Cell
Biol 24: 8970–8980
Liu DX, Nath N, Chellappan SP, Greene LA (2005) Regulation of
neuron survival and death by p130 and associated chromatin
modiﬁers. Genes Dev 19: 719–732
LiuK,LinF-T,RuppertJM,LinW-C(2003)RegulationofE2F1byBRCT
domain-containing protein TopBP1. Mol Cell Biol 23: 3287–3304
Logan N, Graham A, Zhao X, FisherR, Maiti B, Leone G, Thangue NBL
(2005) E2F-8: an E2F family member with a similar organization of
DNA-binding domains to E2F-7. Oncogene 24: 5000–5004
Ma HW, Zhao XM, Yuan YJ, Zeng AP (2004) Decomposition of
metabolic network into functional modules based on the global
connectivity structure of reaction graph. Bioinformatics 20: 1870–
1876
Magae J, Wu CL, Illenye S, Harlow E, Heintz NH (1996) Nuclear
localization of DP and E2F transcription factors by heterodimeric
partnersandretinoblastomaproteinfamilymembers.JCellSci109:
1717–1726
Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T
(2000) Regulation of E2F1 activity by acetylation. EMBO J 19:
662–671
Mi H, Guo N, Kejariwal A, Thomas PD (2007) PANTHER version 6:
protein sequence and function evolution data with expanded
representation of biological pathways. Nucleic Acids Res 35:
D247–D252
MorrisE,DysonN(2001)Retinoblastomaproteinpartners.AdvCancer
Res 82: 1–54
MuchardtC,YanivM(2001)WhentheSWI/SNFcomplexremodelsthe
cell cycle. Oncogene 20: 3067–3075
Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E,
Prosperini E, Vigo E, Oliner JD, Helin K (2001) E2Fs regulate the
expression of genes involved in differentiation, development,
proliferation, and apoptosis. Genes Dev 15: 267–285
Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M,
Zacny VL (2001) Biological activities and molecular targets of the
human papillomavirus E7 oncoprotein. Oncogene 20: 7888–7898
Nevins JR (2001) The Rb/E2F pathwayand cancer. Hum Mol Genet 10:
699–703
Nielsen SJ, Schneider R, Bauer U-M, Bannister AJ, Morrison A,
O’Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE,
Kouzarides T (2001) Rb targets histone H3 methylation and HP1 to
promoters. Nature 412: 561–565
Novak B, Tyson JJ, Gyorffy B, Csikasz-Nagy A (2007) Irreversible cell-
cycle transitions are due to systems-level feedback. Nat Cell Biol 9:
724–728
Oda K, Kitano H (2006) A comprehensive map of the toll-like receptor
signaling network. Mol Syst Biol 2: 2006.0015
Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive
pathway map of epidermal growth factor receptor signaling. Mol
Syst Biol 1: 2005.0010
Ogawa H, Ishiguro K, Gaubatz S, Livingston DM, Nakatani Y (2002) A
complex with chromatin modiﬁers that occupies E2F- and Myc-
responsive genes in G0 cells. Science 296: 1132–1136
Planas-Silva MD, Weinberg RA (1997) The restriction point and
control of cell proliferation. Curr Opin Cell Biol 9: 768–772
PowersJT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG
(2004) E2F1 uses the ATM signaling pathway to induce p53 and
Chk2 phosphorylation and apoptosis. Mol Cancer Res 2: 203–214
Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi AL (2002)
Hierarchical organization of modularity in metabolic networks.
Science 297: 1551–1555
Rayman JB, Takahashi Y, Indjeian VB, Dannenberg J-H, Catchpole S,
Watson RJ, te Riele H, Dynlacht BD (2002) E2F mediates cell cycle-
dependent transcriptional repression in vivo by recruitment of an
HDAC1/mSin3B corepressor complex. Genes Dev 16: 933–947
Sackmann A, Heiner M, Koch I (2006) Application of Petri net based
analysis techniques to signal transduction pathways. BMC
Bioinformatics 7: 482
Saez-Rodriguez J, Mirschel S, Hemenway R, Klamt S, Gilles ED,
Ginkel M (2006) Visual setup of logical models of signaling and
regulatory networks with ProMoT. BMC Bioinformatics 7: 506
Sa ´nchez-BeatoM,Sa ´nchezE,Garcı ´aJF ,P e ´rez-RosadoA,MontoyaMC,
Fraga M,ArtigaMJ, Navarrete M,AbrairaV, Morente M,EstellerM,
Koseki H, Vidal M, Piris MA (2004) Abnormal PcG protein
expression in Hodgkin’s lymphoma. Relation with E2F6 and NF?
B transcription factors. J Pathol 204: 528–537
Schilling CH, Letscher D, Palsson BO (2000) Theory for the systemic
deﬁnition of metabolic pathways and their use in interpreting
metabolic function from a pathway-oriented perspective. J Theor
Biol 203: 229–248
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D,
Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software
environment for integrated models of biomolecular interaction
networks. Genome Res 13: 2498–2504
Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer.
Cancer Cell 2: 103–112
Stelling J, Klamt S, Bettenbrock K, Schuster S, Gilles ED (2002)
Metabolic network structure determines key aspects of
functionality and regulation. Nature 420: 190–193
Stevaux O, Dyson NJ (2002) A revised picture of the E2F
transcriptional network and RB function. Curr Opin Cell Biol 14:
684–691
A comprehensive map of RB/E2F pathway
L Calzone et al
& 2008 EMBO and Nature Publishing Group Molecular Systems Biology 2008 11Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG,
Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, Graham A,
Southgate J, Asselain B, Allory Y, Abbou CC, Albertson DG,
Thiery JP, Chopin DK, Pinkel D, Radvanyi F (2006) Regional copy
number-independent deregulation of transcription in cancer. Nat
Genet 38: 1386–1396
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL,
Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES,
Mesirov JP (2005) Gene set enrichment analysis: a knowledge-
based approach for interpreting genome-wide expression proﬁles.
Proc Natl Acad Sci USA 102: 15545–15550
Trimarchi JM, Fairchild B, Wen J, Lees JA (2001) The E2F6
transcription factor is a component of the mammalian
Bmi1-containing polycomb complex. Proc Natl Acad Sci USA 98:
1519–1524
Tsantoulis PK, Gorgoulis VG (2005) Involvement of E2F transcription
factor family in cancer. Eur J Cancer 41: 2403–2414
Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA (1997) E2F
activity is regulated by cell cycle-dependent changes in subcellular
localization. Mol Cell Biol 17: 7268–7282
Vidal A, Koff A (2000) Cell-cycle inhibitors: three families united by a
common cause. Gene 247: 1–15
Vismara P (1997) Union of all the minimum cycle bases of a graph.
Electr J Comb 4: 73–87
Wang B, Liu K, Lin F-T, Lin W-C (2004) A Role for 14-3-3\{tau\} in
E2F1 stabilization a. J Biol Chem 279: 54140–54152
WeinbergRA (1995) Theretinoblastomaproteinand cell cycle control.
Cell 81: 323–330
ZhangHS,GavinM,DahiyaA,PostigoAA,MaD,LuoRX,HarbourJW,
Dean DC (2000) Exit from G1 and S phase of the cell cycle is
regulated by repressor complexes containing HDAC-Rb-hSWI/SNF
and Rb-hSWI/SNF. Cell 101: 79–89
Zinovyev A, Viara E, Calzone L, Barillot E (2007) BiNoM: a Cytoscape
plugin for manipulating and analyzing biological networks.
Bioinformatics; advance online publication 16 November 2007;
doi:10.1093/bioinformatics/btm553
MolecularSystemsBiologyisanopen-accessjournal
publishedbyEuropeanMolecularBiologyOrganiza-
tion and Nature Publishing Group.
This article is licensed under a Creative Commons Attribution-
Noncommercial-Share Alike 3.0 Licence.
A comprehensive map of RB/E2F pathway
L Calzone et al
12 Molecular Systems Biology 2008 & 2008 EMBO and Nature Publishing Group